Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01E PROTEIN KINASE INHIBITORS
L01EL Bruton's tyrosine kinase (BTK) inhibitors
L01EL02 Acalabrutinib
D12704 Acalabrutinib maleate hydrate (JAN) <JP/US>
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
429 Miscellaneous
4291 Other Antitumors
D12704 Acalabrutinib maleate hydrate (JAN)
Drug groups [BR:br08330]
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG02022 BTK inhibitor
DG03089 Acalabrutinib
D12704 Acalabrutinib maleate hydrate
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG03089 Acalabrutinib
D12704 Acalabrutinib maleate hydrate
Target-based classification of drugs [BR:br08310]
Protein kinases
Non-receptor tyrosine kinases
TEC family
BTK
D12704 Acalabrutinib maleate hydrate (JAN) <JP/US>
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D12704
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D12704
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D12704
Drug groups [BR:br08330]
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG02022 BTK inhibitor
DG03089 Acalabrutinib
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG03089 Acalabrutinib